Sanuwave Health (NASDAQ:SNWV) Downgraded to “Strong Sell” Rating by Zacks Research

Zacks Research lowered shares of Sanuwave Health (NASDAQ:SNWV) from a hold rating to a strong sell rating in a research note released on Monday morning,Zacks.com reports.

Other equities analysts have also issued research reports about the company. Weiss Ratings raised Sanuwave Health from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday. Wall Street Zen downgraded shares of Sanuwave Health from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Roth Mkm reaffirmed a “buy” rating and issued a $47.00 target price (down from $53.00) on shares of Sanuwave Health in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $51.00.

Sanuwave Health Stock Down 0.6%

SNWV stock opened at $17.29 on Monday. Sanuwave Health has a twelve month low of $16.27 and a twelve month high of $46.58. The company has a quick ratio of 1.05, a current ratio of 1.38 and a debt-to-equity ratio of 10.08. The firm has a market cap of $148.52 million, a PE ratio of -108.06 and a beta of 1.32. The business has a 50 day moving average of $23.63 and a 200 day moving average of $29.06.

Sanuwave Health (NASDAQ:SNWV) last announced its quarterly earnings data on Thursday, March 26th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.14). Sanuwave Health had a net margin of 26.64% and a negative return on equity of 141.56%. The company had revenue of $13.09 million for the quarter, compared to analysts’ expectations of $13.23 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Stonebridge Wealth Management LLC purchased a new stake in shares of Sanuwave Health during the second quarter valued at $1,696,000. CenterBook Partners LP raised its position in Sanuwave Health by 528.7% in the 3rd quarter. CenterBook Partners LP now owns 87,947 shares of the company’s stock worth $3,296,000 after buying an additional 73,959 shares during the last quarter. Rice Hall James & Associates LLC purchased a new position in Sanuwave Health in the 3rd quarter worth about $1,023,000. Barclays PLC lifted its stake in Sanuwave Health by 12.7% during the 4th quarter. Barclays PLC now owns 11,610 shares of the company’s stock valued at $346,000 after acquiring an additional 1,306 shares during the period. Finally, Rhumbline Advisers lifted its stake in Sanuwave Health by 40.8% during the 3rd quarter. Rhumbline Advisers now owns 9,051 shares of the company’s stock valued at $339,000 after acquiring an additional 2,624 shares during the period. 42.53% of the stock is owned by institutional investors.

About Sanuwave Health

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.